2016
Improved i.p. drug delivery with bioadhesive nanoparticles
Deng Y, Yang F, Cocco E, Song E, Zhang J, Cui J, Mohideen M, Bellone S, Santin AD, Saltzman WM. Improved i.p. drug delivery with bioadhesive nanoparticles. Proceedings Of The National Academy Of Sciences Of The United States Of America 2016, 113: 11453-11458. PMID: 27663731, PMCID: PMC5068292, DOI: 10.1073/pnas.1523141113.Peer-Reviewed Original ResearchConceptsChemotherapeutic agentsUterine serous carcinoma patientsBioadhesive nanoparticlesAdministration of chemotherapySerous carcinoma patientsPotent chemotherapeutic agentPeritoneal carcinomatosisCarcinoma patientsPeritoneal spaceAbdominal cavityLow systemic toxicityLymphatic drainageTherapeutic efficacyMesothelial cellsHigh therapeutic efficacySystemic toxicityFast clearanceEfficacy of nanoparticlesEfficacyFree EBBiodegradable nanoparticlesNanoparticlesDrug deliveryCarcinomatosisChemotherapy
2014
HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges
Buza N, Roque DM, Santin AD. HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges. Archives Of Pathology & Laboratory Medicine 2014, 138: 343-50. PMID: 24576030, DOI: 10.5858/arpa.2012-0416-ra.Peer-Reviewed Original ResearchConceptsEndometrial carcinomaHER2/neuPromising therapeutic targetHER2 testingClinical responseTherapeutic targetHumanized monoclonal immunoglobulin G1 antibodyMonoclonal immunoglobulin G1 antibodyUterine serous carcinomaImmunoglobulin G1 antibodyNovel therapeutic strategiesEndometrial cancerSerous adenocarcinomaSerous carcinomaCase reportDiagnostic challengeHER2 overexpressionPathogenetic featuresClinical studiesG1 antibodyTherapeutic strategiesCarcinomaTherapeutic efficacyStandardized criteriaTherapy